Skip to content

study to the evaluate non-inferiority Compared two local anesthetic for orthopedic procedures on the lower limbs

Phase III study to evaluate the noninferiority of levobupivacaine with excess 50% (levobupivacaine S75: R25) heavy compared to racemic bupivacaine (bupivacaine S50: R50) heavy in spinal anesthesia for lower limb orthopedic procedures

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
REBEC
Registry ID
RBR-39z9pb
Enrollment
Unknown
Registered
2015-02-25
Start date
2015-07-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

broken leg, foot and / or ankle injury in the ankle or foot.

Interventions

Experimental group: 60 women or men who have an indication for surgery of the lower limbs receive the anesthetic drug levobupivacaine at a single dose of 3 mL, which will be administered via intrathec
Drug

Sponsors

Faculdade de Medicina do ABC
Lead Sponsor
Cristalia Produtos Químicos Farmacêuticos Ltda
Collaborator

Eligibility

Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who agree to participate in the study and signed the consent form, both sexes, aged between 18 and 80 years inclusive, ASA I or ASA II with indication for spinal anesthesia for orthopedic surgery of the lower limbs

Exclusion criteria

Exclusion criteria: Absolute or relative contraindications to spinal anesthesia ; intolerance or hypersensitivity to local anesthetics or components of the formula , spinal cord injuries , peripheral neuropathy or other neurological disorders that lead to disturbances of sensation and / or motor function , dementia , mental retardation and other important cognitive changes ; obesity with body mass index ? 35 or difficulty in executing the puncture ; anatomical difficulty column in the Investigator's opinion , previous surgery of the spine ; polytrauma ; tattoo at the puncture site , alcoholism , substance abuse , history severe Stevens- Johnson anaphylactic reactions, changes in safety tests ( INR > 1.4 , platelet count 200mg/dl , bradyarrhythmias , heart block , frequent premature ventricular beats or saved evident on ECG ) ; participation in any clinical trial within the 12 months preceding their inclusion , pregnancy or lactation, any other condition that , in the Investigator's opinion , may lead to increased risk to the patient.

Design outcomes

Primary

MeasureTime frame
Latency time evaluation (waiting) for sensory block by the time interval spent between the withdrawal of the needle at the end of the local anesthetic injection and the absence of response to sensory impulse.

Secondary

MeasureTime frame
Motor block degree evaluation by modified Bromage scale; Motor block duration measured by the time interval between the withdrawal of the needle after the puncture and the return to level 0 in the modified Bromage scale; Cardiovascular safety evidenced by the incidence and severity of changes Blood pressure and heart rate measurements automatically by the device; Anesthesia failure: classification will be evaluated in total failure or partial failure identified by the absence or presence of sensory and motor aspects); Presence of adverse events identified by means of unexpected effects.

Countries

Brazil

Contacts

Public ContactVanessa Assao

Cristalia Produtos Químicos Farmacêuticos Ltda

vanessa.assao@cristalia.com.br+55(11)37236400

Outcome results

None listed

Source: REBEC (via WHO ICTRP)